We describe the first reported transmission to a human of simian foamy virus (SFV) from a free-ranging population of nonhuman primates in Asia. The transmission of an exogenous retrovirus, SFV, from macaques (Macaca fascicularis) to a human at a monkey temple in Bali, Indonesia, was investigated with molecular and serologic techniques. Antibodies to SFV were detected by Western blotting of serum from 1 of 82 humans tested. SFV DNA was detected by nested polymerase chain reaction (PCR) from the blood of the same person. Cloning and sequencing of PCR products confirmed the virus’s close phylogenetic relationship to SFV isolated from macaques at the same temple. This study raises concerns that persons who work at or live around monkey temples are at risk for infection with SFV.

Recent epidemics such as HIV and severe acute respiratory syndrome (SARS) have changed the way we view emerging infectious diseases; these epidemics show that animal reservoirs are important sources of new infectious threats to humans. Contact between humans and animals is a crucial rate-limiting step in this process, although data describing the variables that influence animal-to-human transmission are relatively scarce. Nonhuman primates, by virtue of their genetic, physiologic, and sometimes social similarities to humans, are particularly likely sources of infectious agents that pose a threat to humans (1,2). Data on simian immunodeficiency virus (SIV)/HIV dramatize this point; scientists now theorize that SIVs were transmitted from primates to humans on several occasions (3,4). As a result, concern is increasing that other infectious agents enzootic in primate populations may endanger humans (5).

The family of SIV is 1 of 4 primateborne retroviruses known to infect humans (6). Simian T-cell lymphotropic viruses, enzootic in both Asian and African Old World monkeys and apes, may have repeatedly crossed the species barrier (7,8). The resulting human form of the virus, HTLV, is the etiologic agent of 2 human diseases, adult T-cell leukemia and tropical spastic paresis (9). Serologic studies have demonstrated evidence of primate-to-human transmission of simian retrovirus (SRV), a retrovirus enzootic among Old World monkeys, in laboratory workers exposed to captive primates (10). To date, no disease has been linked to human infection with SRV. Finally, in the past decade, evidence of infection with simian foamy virus (SFV) has been identified in 1% to 4% of persons who come into frequent contact with primates in zoos and primate laboratories and among 1% of bushmeat hunters in Central Africa (11–15).

SFV

SFVs are exogenous retroviruses enzootic in both New and Old World primates (16–18). Phylogenetic analyses of SFVs indicate a species-specific distribution of virus strains not unlike that of SIV among some African primate species (19–23). Among captive primate populations, seroprevalence of antibodies to SFV may reach 100% in adults, with many animals seroconverting before the onset of sexual maturity (19,24; J. Allan, unpub. data). Fewer data are available on the seroprevalence of antibodies to SFV among free-ranging populations of primates. SFV is present in highest concentrations in the saliva of infected laboratory macaques (Macaca mulatta and M. fascicularis) and African green monkeys (Cercopithecus aethiops), which suggests that bites, scratches, and mucosal splashes with
saliva from primates are likely mechanisms of transmission (25–27).

Because SFV is not known to occur naturally in humans, detecting serologic or molecular evidence, or both, of infection in a human, along with a history of close contact with primates, constitutes strong evidence for primate-to-human transmission, i.e., a marker for cross-species transmission (28). Existing serologic and molecular techniques can sensitively and specifically detect human SFV infections (29).

Primates and humans come into contact in a variety of contexts in Asia, including owning primate pets, observing performance monkeys, participating in ecotourism activities, hunting primates for bushmeat, and visiting monkey temples (30,31). Monkey temples are religious sites that have, over time, become associated with populations of free-ranging primates. Monkey temples are common throughout southern and Southeast Asia, where primates play an important role in culture. Asia’s monkey temples annually bring millions of people, including hundreds of thousands of tourists, from around the world into close proximity with free-ranging primates (32–34). Worldwide, monkey temples may account for more human-primate contact than any other context.

In Bali, ≈45 temple sites contain substantial populations of free-ranging macaques (33). Those who spend the most time in or around monkey temples include workers who maintain the temples; nuns, monks, and others who live on or around temple grounds; merchants who sell a variety of goods to tourists; and farmers whose fields are raided by macaques. Worshippers and tourists may also come into contact with temple macaques. These temples are thus an important context in which to investigate cross-species transmission of infectious agents.

Serologic data on free-ranging Southeast Asian macaques, though incomplete, suggest that SFV is enzootic among these macaque populations and that corresponding rates of SFV infection are high (80%–100%) (L. Jones-Engel, unpub. data). We hypothesized that humans who come into contact with these macaques might similarly show evidence of infection with SFV and investigated this proposition among a group of persons who worked at or around the Sangeh monkey temple in Bali, Indonesia.

**Methods**

**Study Site: Sangeh Monkey Temple**

The Sangeh monkey temple is in central Bali, Indonesia, ≈20 km north of Denpasar, Bali’s most populous city. The 17th-century Hindu temple complex at Sangeh serves the surrounding community and is a popular domestic and international tourist destination. Approximately 200 free-ranging *M. fascicularis* roam throughout the 6-hectare temple complex and into the surrounding rice fields and farms. Most of the macaques’ caloric intake is from daily provisions provided by temple workers and food given to them by visitors.

**Human Participant Sampling**

In July 2000, as part of a larger study on the epidemiology of exposure to primateborne viruses at the Sangeh monkey temple, 82 workers from Sangeh agreed to participate in the present study (32). After informed consent was obtained, a questionnaire designed to elicit demographic data as well as data describing the frequency and type of exposure to Sangeh’s macaques was administered in Bahasa Indonesia, the national language of Indonesia. Subsequently, 10 mL of blood was withdrawn from each participants antecubital vein, 6 mL was centrifuged to extract serum, and the remainder was mixed with EDTA. Serum specimens and whole blood were then stored at −20°C.

**Macaque Sampling**

In July 2000, 38 macaques within the Sangeh monkey temple area and surrounding forest were darter opportunistically and sedated with 3 mg/kg of Telazol (tiletamine HCl/zolazepam HCl). Following universal precautions, researchers withdrew 10 mL of blood from each macaque’s femoral vein. The macaques were closely monitored during anesthesia and recovery. Six milliliters of blood was placed in a serum separator tube and centrifuged in the field to extract the serum. The remaining blood was placed in a tube containing EDTA. Sera and whole blood were then frozen and stored at −20°C.

**Western Blot Analysis**

Western blot immunoassays were performed with a few modifications (21). Briefly, human foreskin fibroblast cells were infected with SFVbab1 (an isolate from a baboon) and maintained until notable cytopathologic changes were observed (19). Culture supernatant fluid containing virus was harvested, and SFV was purified through a 20% sucrose cushion, separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and the antigens were blotted onto nitrocellulose sheets. The nitrocellulose paper was blocked with 3% bovine serum albumin and subsequently incubated with serum at a dilution of 1:40. Viral proteins were detected with the streptavidin-biotin system (Amersham Inc., Arlington Heights, IL, USA) by using diaminobenzidine as the substrate for color development. The criterion used for a positive sample was antibody reactivity to both p70 and p74 gag-related proteins (19).

**PCR Detection of SFV**

DNA was purified from whole blood by using the QIAamp DNA Blood Mini Kit (Qiagen, Inc., Valencia,
CA, USA). Briefly, 20 µL protease and 200 µL buffer AL were combined with 200 µL whole blood and incubated at 56°C for 10 min. After incubation, 200 µL ethanol was added, and the entire mixture was applied to a QIAamp spin column. The purified DNA was eluted from the column with 70 µL nuclease-free water, and concentration was determined spectrophotometrically at optical density 260 nm.

The presence of SFV DNA was determined by using nested PCR. Five hundred ng purified DNA was combined with a PCR reaction mixture with a final concentration of 10 mmol/L Tris (pH 9.0), 50 mmol/L KCl, 0.1% Triton X-100, 2 mmol/L MgCl₂, 200 µmol/L each dNTP, 0.15 mg/mL BSA, 1 µL Taq polymerase, and 400 nmol/L of each primer in a total volume of 50 µL. The following primer pairs were used: first round, forward 5´-CAG ATT CCC GAT TTA CAC CAC TCC CAC TAG ATG CCT C-3´ and second round, forward 5´-CCA GAA TCT CTT CAT ACT AAC TA-3´ and reverse 5´-GAT GGT TCC CTA AGC AAG GC-3´ (29). “Touchdown PCR” was used for both rounds with reaction conditions of initial denaturation at 94°C for 2 min, followed by 7 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s, with a 2°C decrease in annealing temperature per cycle to 48°C, followed by 33 cycles of 94°C for 30 s, 48°C for 30 s, and 72°C for 45 seconds with a final extension at 72°C for 2 min. Second-round conditions were the same, except 19 cycles were used instead of 33.

Twenty µL of the PCR reaction underwent electrophoresis on a 1% low melting point agarose gel. DNA bands (365-bp product) were excised from the gel and purified by using Wizard PCR Preps DNA Purification System (Promega Corp., Madison, WI, USA). The PCR product was ligated into the pCR 2.1-TOPO vector by using the TOPO TA Cloning Kit (Invitrogen Corp., Carlsbad, CA, USA.). An SFV DNA plasmid (pSFV-1Lgp), representing long terminal repeat, gag, and pol of SFV-1, was included as a positive PCR control and for determining sensitivity of detection by serial dilution (provided by A. Mergia). TOP10 cells were transformed with the ligation reaction, plated onto Luria broth agar plates containing 50 µg/mL kanamycin, and incubated overnight at 37°C. Miniscreen DNA was purified by using Wizard Plus Minipreps DNA Purification System (Promega). Samples were sequenced with the ABI 373 automated fluorescent sequencer using BigDye Terminator cycle sequencing chemistry (Applied Biosystems, Foster City, CA, USA).

Amplification of Mitochondrial Sequences

Five hundred ng purified DNA from whole blood was combined in a PCR reaction mixture with a final concentration of 10 mmol/L Tris (pH 9.0), 50 mmol/L KCl, 0.1% Triton X-100, 2.5 mmol/L MgCl₂, 200 µmol/L each dNTP, 0.15 mg/mL BSA, 1 U Taq polymerase, and 400 nmol/L of each primer in a total volume of 50 µL. The following primers were used: forward, 12SA, 5´-CTG GGA TTA GAG ACC CCT CAC TCT 3´, and reverse, 12SO, 5´-GTC GAT ATT GAT GGT TCC CTA AGC AAG GC-3´ (35). Cycling conditions were the following: initial denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 5 min, with a final extension at 72°C for 5 min. The 101-bp product underwent electrophoresis and was processed for DNA sequencing essentially as described for SFV.

The alignments were made in Bioedit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and ClustalX 1.81 (ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX/). Columns in the alignment in which gaps had been inserted in regions with insertions, and deletions were stripped before the analyses. DNA trees were created with the neighbor-joining method by using the Phylip program (DNAdist; Neighbor), and the output was generated with Treeview (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). The GenBank accession numbers for the SFV and mitochondrial DNA sequences reported here are AY628152-69 and AY633510-39, respectively.

Results

Seroprevalence of SFV among Macaques

The seroprevalence of SFV among the Sangeh macaques is presented in Table 1. Thirty-eight macaques (29 males and 9 females; 4 juveniles, 6 subadults, 28 adults) were sampled. Thirty-four (89.5%) of the 38 macaques were antibody positive. All 9 females were SFV seropositive. SFV seroprevalence in this free-ranging macaque population was consistent with seroprevalence studies done in captive (25) and other free-ranging macaque populations (L. Jones-Engel, unpub. data).

Table 1. Seroprevalence of antibodies to simian foamy virus among Sangeh macaques (Macaca fascicularis)

| Age group | No. Western blot positive/total (%) |
|-----------|-----------------------------------|
| Juvenile  | 2/4 (50.0)                        |
| Male      | 2/4 (50.0)                        |
| Subadult  | 6/6 (100.0)                       |
| Male      | 4/4 (100.0)                       |
| Female    | 2/2 (100.0)                       |
| Adult     | 28/28 (92.9)                      |
| Male      | 19/21 (90.5)                      |
| Female    | 7/7 (100.0)                       |
| All ages  | 34/38 (89.5)                      |
| Male      | 25/29 (86.2)                      |
| Female    | 9/9 (100.0)                       |

*Juveniles are defined as 1–3 years of age, subadults as 3–5 years of age, adults as >5 years of age.
Human Participant Exposure Data

Nearly two thirds of the study sample was male (62.2%), and the mean age of the study participants was 35 years (Table 2). Of participants who reported being exposed, 23 (28.0%) of 82 persons reported having been bitten by the temple’s macaques (Table 3). Five of the 23 reported being bitten more than once. Thirty-one (37.8%) of 82 reported having been scratched, including 9 persons who had been scratched more than once. In total, 37 (45.1%) of 82 reported having been either bitten or scratched.

Of the 82 persons whose serum was tested for antibodies to SFV, 81 had negative results by Western blot. Serum from a 47-year-old farmer (BH66) was reactive to SFV gag proteins, p70/p74 (Figure 1). This man reported that he visited the monkey temple every day and had previously been bitten once and scratched on more than one occasion by macaques there. He reported that the bite and scratches, which occurred on his hands and toes, had bled and that he had washed the wounds and applied traditional medicines. He denied owning or coming into contact with a pet primate. He also denied hunting primates or consuming primate meat.

Detection of SFV DNA in a Person from Bali

To determine whether SFV was present in humans and macaques, we performed nested PCR amplification of SFV by using conserved primers designed to detect macaque SFV (29). SFV was detected in the macaques tested, as well as in the 1 human participant (BH66), whose serum contained antibodies to SFV. Blood samples from all 81 human participants that were seronegative for antibodies to SFV were also negative for SFV by PCR. The limits of sensitivity for nested PCR were 1–10 SFV DNA copies per 500 ng cellular DNA, as determined by dilution of a positive control plasmid.

Quantitative PCR products of BH66, 5 of the Sangeh macaques (M. fascicularis), and 13 pet macaques (M. tonkeana, M. maura, and M. fascicularis) from Sulawesi, Indonesia, were cloned at least twice, sequenced, and compared with published sequences from a rhesus macaque (M. mulatta) (SFV-Imac, M55279), an African green monkey (Cercopithecus aethiops) (SFV-3agm, M74895), and a chimpanzee (Pan troglodytes) (SFVcpz, U04327). As shown in Figure 2, SFV from BH66 was most closely related to an SFV sequence amplified from 1 of the macaques at the Sangeh monkey temple (BP6). To verify that the BH66 sample was of human origin and not a mislabeled sample from an SFV-infected monkey, we amplified a small fragment from the 12S ribosomal mitochondrial DNA from 2 healthy unexposed humans, BH66, several macaque species, and African green monkeys; cloned the products; and derived DNA sequences.

Phylogenetic analysis (Figure 3) showed that the human DNA sample grouped with mitochondrial DNA sequences from humans, confirming that the BH66 sample was from a human. Lymphocytes from BH66 were not available for isolation of SFV directly.

Discussion

Human Infection with SFV at the Sangeh Monkey Forest

This report documents the first case of SFV infection in a person with known exposure to free-ranging Asian primates. Antibodies to SFV were detected in serum, and SFV genomic segments were amplified from blood of the infected person. Because PCR is prone to contamination, which leads to false-positive results, PCR products were sequenced and compared to SFV from other macaque species. Phylogenetic analysis showed that SFV amplified from the infected human was most similar to SFV from M. fascicularis at the Sangeh monkey temple. Although ascertaining exactly how or when the person acquired his infection was not possible, he did report having been bitten once and scratched on a number of occasions by macaques at Sangeh. He denied other past contacts with primates.

Because only 1 infected person was detected and our sample size was limited (82 persons), we cannot estimate the prevalence of SFV infection in this human sample. Previous research on naturally acquired SFV infection among bushmeat hunters in Central Africa found 10 who seroconverted in a population of 1,099 (1%), of which 3 also had positive results by PCR. Surveillance of larger

| Table 3. Prevalence of reported bite and scratch injuries |
|----------------------------------------------------------|
| Descriptor | No. (%) |
| Bitten | 23 (28.0) |
| Bitten more than one | 5 (6.1) |
| Scratched | 31 (37.8) |
| Scratched more than once | 9 (11.0) |
| Bitten or scratched | 37 (45.1) |
| Possessed food at time of injury | 35 (43.6) |
| All participants | 82 (100.0) |

| Table 2. Human study population, demographic characteristics |
|---------------------------------------------------------------|
| Demographic characteristic | No. (%) |
| All participants | 82 (100.0) |
| Age group (y) | |
| <20 | 9 (11.0) |
| 20–29 | 23 (28.0) |
| 30–39 | 20 (24.4) |
| 40–49 | 22 (26.8) |
| >49 | 8 (9.7) |
| Sex | |
| Male | 51 (62.2) |
| Female | 31 (37.8) |
numbers of persons exposed to primates at monkey
Temples is necessary to estimate the risk of SFV infection
in this context.

Monkey Temples in Bali as Contexts
for Primate-Human Contact

Human and macaque sympatry in Southeast Asia dates
back as far as 25,000 years, as evidenced by remains at
Niah Cave in Borneo (37). Hindu and Buddhist temples are
a relatively recent addition to the landscape, first appearing
1,000 to 4,000 years ago. Contemporary human-macaque
commensalism at each monkey temple is shaped by the
behavioral characteristics of the particular monkey population
as well as the community’s unique geographic, social,
religious, and economic factors. Human-macaque contact
differs at the various monkey temples. At Sangeh, where
tourism has become an important economic resource,
macaques depend on visitor feeding for most of their nutri-
tion and have learned to climb on visitors’ heads and shoulders to obtain food. Local photographers, who make a
living photographing visitors with monkeys, encourage this
behavior. Macaques, sometimes provoked by visitors, can
become aggressive and will bite or scratch people.

The Sangeh Temple Committee, which manages the
Sangeh Monkey Forest, estimates ≈250 persons work in
and around the monkey forest. Of the 82 persons who par-
ticipated in the present study, 28% had been bitten by a
macaque, and 6% had been bitten more than once. In com-
parison, 700,000 tourists visit the 4 main monkey temples
on the island of Bali (Padangtegal/Ubud, Sangeh, Alas
Kedaton, and Uluwatu) annually and as many as 5% of
these visitors are bitten by macaques (A. Fuentes, unpub.
data). These data suggest that visitors receive the prepon-
derence of macaque bites.

Importance of SFV Infection in Humans

The literature describes ≈40 cases of human infection
with SFV. Long-term follow-up data are unavailable for
many of these cases. However, no disease has been linked
to SFV among infected humans. Furthermore, no cases of
human-to-human transmission have been described, even
among those receiving transfusions of blood products from
a worker at a primate center who was later shown to be
infected with SFV (38).

Notwithstanding, more data are needed before SFV can
be proclaimed a “virus without a disease.” First, SFV
infection has not been extensively studied in immunocom-
promised persons, so whether SFV has a more aggressive
course in an immunologically “permissive” environment is
unknown. Two persons died shortly after receiving baboon
liver transplants in 1994, and SFV was detected in the blood and tissues of both at autopsy (39). More research in this area is needed. Moreover, little is known about the epidemiology of SFV among wild primates. Although SFV infection in humans has not culminated in any observable symptoms, SFV strains may differ in their capacity to infect or cause disease in humans. Finally, whether SFV can adapt in humans after transmission and potentially lead to disease needs to be examined.

Implications and Recommendations for Public Health

The recent SARS epidemic vividly demonstrates how the economic infrastructure and dense population of Asia facilitate the rapid international spread of disease. The combination of large primate reservoirs, prevalent human-primate contact, a growing immunocompromised population, and advanced infrastructure in Asia increases the likelihood of a primateborne zoonosis emerging on this continent.

The demonstration of SFV transmission in the context of a monkey temple in Bali points to a broad public health concern: other enzootic primate infectious agents may cross the species barrier and cause significant morbidity and mortality in human populations. Given our lack of knowledge of the effects of SFV, as well as the poorly defined risk of other primateborne zoonoses, steps should be taken to decrease the risks of cross-species transmission among the many persons who visit these sites. Previous data on both worker and visitor exposure to macaques at monkey temples suggest that human behaviors, especially the practice of feeding macaques, is a risk factor for being bitten or scratched (33,34). We have recommended that monkeys be fed only by specially trained personnel who minimize physical contact with monkeys. Such restrictions have been successfully employed at other monkey forests in Asia. For example, Singapore’s Bukit Timah Nature Reserve has nearly 200 free-ranging macaques (M. fascicularis), and in 2002, an estimated 380,000 visitors made use of the reserve’s trail system, yet contact between monkeys and visitors at Bukit Timah is rare. This finding may be ascribed to the park’s policy, enforced by stiff fines, of prohibiting visitors from feeding macaques.

Conclusions

This study reports the first case of human SFV infection in Asia and also, for the first time, links natural transmission of SFV to a person to a specific population of primates. Our findings suggest that workers in and around monkey temples can become infected with SFV. By implication, visitors to monkey temples, especially those who are bitten by a macaque, may also be at risk for SFV infection. Because many visitors to monkey temples are international travelers, these findings have ramifications for the potential global spread of primateborne infectious agents. Demonstrating natural cross-species transmission in a context that does not involve hunting for bushmeat implies that other contexts of primate-human contact may also facilitate the transmission of simian pathogens. These data point to the need for further research into SFV transmission in other contexts, including pet ownership and performance animals, as well as in the diverse geographic areas where humans and primates come into contact. Such research will help describe the overall picture of the
emergence of primateborne pathogens such as HIV/SIV and will form a scientific basis for guiding policies and programs to deter the spread of emerging zoonotic pathogens.

Acknowledgments

We thank Drs. P. Sukrama, D. Cohn, J. Heidrich, R. Grant, R. Kyes, A. Stone and J. Froehlich, as well as Pak Budi, Pak Nyoman, the Sangeh Temple Committee, G. Emel, Y. Singeo, G. Kelemen, H. Engel, L. Engel, B. Beresic, and Singapore Airlines for facilitating this research. We also thank The Indonesian Directorate of Nature Conservation and Wildlife Management. We are grateful to Ayalew Mergia for providing the pSFV-1Lgp plasmid.

This research was approved by the University of New Mexico’s Human Research and Review Committee and Institutional Animal Care and Use Committee. It was supported in part by grants from the Chicago Zoological Society, Unconventional Concepts, Inc., the University of New Mexico’s Student Research and Allocations Committee, the University of New Mexico School of Graduate Studies, NIH/NICRR grant P51 RR00166 (L.J.E) and NIH grant P51 RR013986-06 (J.S.A.).

Dr. Jones-Engel is a research scientist at the University of Washington’s National Primate Research Center. Her research focuses on bidirectional pathogen transmission between humans and primates in Asia and its implications for public health and primate conservation.

References

1. Wolfe ND, Escalante AA, Karesh WB, Kilbourne A, Spielman A, Lal AA. Wild primate populations in emerging infectious disease research: The missing link? Emerg Infect Dis. 1998;4:149–58.
2. Weiss RA. Cross-species infections. Curr Top Microbiol Immunol. 2003;278:47–71.
3. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 1999;397:436–41.
4. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH. The origins of acquired immune deficiency viruses: where and when? Philos Trans R Soc Lond B Biol Sci. 2001;356:867–76.
5. Murphy FA. A perspective on emerging zoonoses. In: Burroughs T, Cummins LB, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 1999;397:436–41.
6. Khabbaz RF, Heneine W, George JR, Parekh B, Rowe T, Woods T, et al. Brief report: infection of a laboratory worker with simian immunodeficiency virus type D retrovirus in persons occupationally exposed to nonhuman primates. J Virol. 2001;75:1783–9.
7. Switzer WM, Bhullar V, Shanmugam V, Cong M, Parekh B, Lerche NW, et al. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol. 2004;78:2780–9.
8. Wolfe ND, Switzer WM, Carr JK, Bhullar VB, Shanmugam V, Tamoufe U, et al. Naturally acquired simian retrovirus infections among Central African hunters. Lancet. 2004;363:932–7.
9. Brooks JI, Eurling R, Pilon RG, Smith JW, Switzer WM, Sandstorm PA. Cross-species retroviral transmission from macaques to human beings. Lancet. 2002;360:387–8.
10. Sandstorm PA, Phan KO, Switzer WM, Fredeking T, Chapman L, Heneine W, Folks TM. Simian foamy virus infection among zoo keepers. Lancet. 2000;355:551–2.
11. Calattini S, Mausclere P, Torevoye P, Froment A, Saib A, Gessain A. Interspecies transmission of simian foamy viruses from chimpanzees and gorillas to Bantous and Pygmies hunters in Southern Cameroon. Proceedings of the 5th International Foamy Virus Conference; 2004 Jul 9–11;Wuerzburg, Germany.
12. Renne R, Friedl E, Schweizer M, Fleps U, Turek R, Neumann-Haefelin D. Genomic organization and expression of simian foamy virus type 3 (SFV-3). Virology. 1992;186:597–608.
13. Mergia A, Shaw KE, Pratt-Love E, Barry PA, Luciw PA. Simian foamy virus type 1 is a retrovirus which encodes a transcriptional transactivator. J Virol. 1990;64:3598–604.
14. Hussain AI, Shanmugam V, Bhullar VB, Beer BE, Vallet D, Gautier-Hion A, et al. Screening for simian foamy virus infection by using a combined antigen Western blot assay: evidence for a wide distribution among Old World primates and identification of four new divergent viruses. Virology. 2003;309:248–57.
15. Broussard SR, Comuzzie AG, Leighton KL, Leland MM, Whitehead EM, Allan JS. Characterization of new simian foamy viruses from African nonhuman primates. Virology. 1997;237:349–59.
16. Herchenroder O, Renne R, Loncar D, Cobb EM, Murphy KK, Schneider J, et al. Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). J Virol. 1994;201:187–99.
17. Allan JS, Short M, Taylor ME, Su S, Hirsch VM, Johnson PR, et al. Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J Virol. 1991;65:2816–28.
18. Hussain AI, Shanmugam V, Bhullar VB, Beer BE, Vallet D, Gautier-Hion A, et al. Isolation, cloning, and sequencing of simian foamy virus type 3 (SFV-3). Virology. 1992;186:597–608.
19. Haefelin D. Genomic organization and expression of simian foamy virus (HFV). J Virol. 1999;73:7734–44.
20. Karlsson LF, Demoll PJ, Deckmyn M, Van Damme P, Hennion M, et al. Cross-species infections in African green monkeys. J Virol. 2000;74:2062–72.
21. Heberling RL, Kalter SS. Isolation of foamy viruses from baboon (Papio cynocephalus) tissues. Am J Epidemiol. 1975;102:25–9.
22. Falcone V, Leopold J, Clotten J, Urbanyi E, Herchenroder O, Spatz S, et al. Inapparent carriers of simian AIDS type D retrovirus and interspecies transmission of simian foamy virus in persons occupationally exposed to nonhuman primates. J Virol. 2001;75:1783–9.
23. Khan AS, Sears JF, Muller J, Galvin TA, Shahabuddin M. Sensitive assays for isolation and detection of simian foamy retroviruses. J Clin Microbiol. 1999;37:2678–86.
30. Jones-Engel L, Schillaci MA, Engel G. Interaction between humans and nonhuman primates. In Setchell J, Curtis D, editors. Field and laboratory methods in primatology. Cambridge: Cambridge Univ Press; 2003. p.15–24.
31. Jones-Engel L, Engel GA, Schillaci MA. An ethnoprimatological assessment of disease transmission among humans and wild and pet macaques on the Indonesian island of Sulawesi. In: Patterson J, editor. Commensalism and conflict: the primate-human interface. Norman (OK): American Society of Primatologists Publications. In press.
32. Engel GA, Jones-Engel L, Schillaci MA, Suaryana KG, Putra A, Fuentes A, et al. Human exposure to herpesvirus B-seropositive macaques, Bali, Indonesia. Emerg Infect Dis. 2002;8:789–95.
33. Fuentes A, Southern M, Suaryana KG. Monkey forests and human landscapes: is extensive sympatry sustainable for Homo sapiens and Macaca fascicularis in Bali? In: Patterson J, editor. Commensalism and conflict: the primate-human interface. Norman (OK): American Society of Primatologists Publications. In press.
34. Wheatley BP. The sacred monkeys of Bali. Long Grove (IL): Waveland Press; 1998.
35. Poinar H, Kuch M, Paabo S. Molecular analysis of oral polio vaccine samples. Science. 2001;292:743–4.
36. Vartanian JP, Wain-Hobson S. Analysis of a library of macaque nuclear mitochondrial sequences confirms macaque origin of divergent sequences from old oral polio vaccine samples. Proc Natl Acad Sci U S A. 2002;99:7566–9.
37. Sponsel LE. Monkey business? The conservation implications of macaque ethnoprimateology in southern Thailand. In: Fuentes A, Wolfe L, editors. Primates face to face: the conservation implications of human-nonhuman primate interconnections. New York: Cambridge University Press; 2002. p. 288–309.
38. Boneva RS, Grindon AJ, Orton SL, Switzer WM., Shanmugam V, Hussain AI, et al. Simian foamy virus infection in a blood donor. Transfusion. 2002;42:886–91.
39. Allan JS, Broussard SR, Michaels MG, Starzl TE, Leighton KL, Whitehead EM, et al. Amplification of simian retroviral sequences from human recipients of baboon liver transplants. AIDS Res Hum Retroviruses. 1998;14:821–4.

Address for correspondence: Lisa Jones-Engel, University of Washington, National Primate Research Center, HSB I-039, Box 357330, Seattle, WA 98195, USA; fax: 206-543-7959; email: jonesengel@bart.rprc.washington.edu